Successful Treatment of CD19+ Mixed-Phenotype Acute Leukemia With Brexucabtagene Autoleucel Plus Tyrosine Kinase Inhibitor (SOHO 2026) - Sep 1, 2026 - Abstract #CT-976; Location: LEVEL 3, HALL B3; "She underwent induction therapy with a tyrosine kinase inhibitor (TKI), cyclophosphamide, vincristine, and dexamethasone for 2 cycles as well as intrathecal methotrexate and cytarabine, resulting in complete remission (CR) with detectable breakpoint cluster region–Abelson murine leukemia viral oncogene homolog 1 fusion (BCR::ABL1) transcripts by quantitative polymerase chain reaction (qPCR; 0.02%) in bone marrow (BM). In an effort to eliminate minimal residual disease, the patient received 2 cycles of blinatumomab with a TKI, which was complicated by grade 1 cytokine release syndrome (CRS) without improvement in BCR:: ABL1 (post-treatment BM qPCR 0.06%)...Treatment was complicated by grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS; handwriting) treated with dexamethasone and grade 2 CRS (fever and hypotension) treated with tocilizumab... This represents the first reported use of anti-CD19 CAR T-cell therapy for MPAL and supports its feasibility..."
Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR
|
|
Colin Morita 1; Prabesh Gautam MD 2,3; Rebecca Klisovic MD 2,3; Koen van Besien MD PhD 2,3; Molly Gallogly MD PhD 2,3
|